Filing Flows › Altimmune (ALT) › Q1 2025
Altimmune (ALT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Altimmune (ALT) reported revenue of $5K for the first quarter 2025 (Q1 2025), 0% from a year earlier and 0% from the quarter before.
Altimmune, Q1 2025: revenue $5K (0% year over year), net loss $19.6M, operating cash flow −$16.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5K | 0% | 0% |
| Operating profit | −$21.8M | — | — |
| Net earnings | −$19.6M | — | — |
| Operating cash flow | −$16.8M | — | — |
What changed
Revenue was $5K in Q1 2025, roughly flat year over year and roughly flat from the previous quarter.
Operating costs exceeded revenue by $21.8M, an operating margin of -436300.0%. Total costs fell 19% while revenue was flat. The fastest-growing cost line was General & admin (+13%). The quarter ended with a net loss of $19.6M, narrower than the previous quarter's $23.2M loss.
Operating cash flow was −$16.8M. Non-cash charges added back $29K of depreciation and $4.0M of share-based compensation. Working capital and other items used $1.3M.
Questions
What was Altimmune's revenue in the first quarter 2025?
Altimmune (ALT) reported revenue of $5K for the first quarter 2025 (Q1 2025), 0% from a year earlier and 0% from the quarter before.
Source: Altimmune 10-Q on SEC EDGAR.